Claims

[Claim 1]

Use of an aripiprazole intramuscular (IM) depot formulation comprising from 10 mg to 500 mg of aripiprazole in the manufacture of a medicament for treatment of schizophrenia or bipolar disorder I in a patient, wherein the medicament comprises:

two, separate injections of the aripiprazole intramuscular (IM) depot formulation, wherein the aripiprazole intramuscular (IM) depot formulation comprises aripiprazole monohydrate, wherein each injection comprises from 10 mg to 500 mg of aripiprazole, and wherein each injection is to be administered to the patient at separate injection sites chosen from gluteal injection sites, deltoid injection sites, and a gluteal injection site and a deltoid injection site, and

a single dose of oral aripiprazole,

wherein the medicament is to be administered on a first day of an aripiprazole treatment.

[Claim 2]

The use according to claim 1, wherein each of the two, separate injections comprises 300 mg or 400 mg of aripiprazole.

[Claim 3]

The use according to claim 1 or 2, wherein the medicament further comprises a single, maintenance injection of the aripiprazole IM depot formulation to be administered monthly after the first day of the aripiprazole treatment.

[Claim 4]

The use according to claim 3, wherein the single, maintenance injection is chosen from 300 mg and 400 mg of aripiprazole in the aripiprazole IM depot formulation.

[Claim 5]

The use according to claim 4, wherein the single, maintenance injection comprises 400 mg of aripiprazole.

[Claim 6]

The use according to any one of claims 3 to 5, wherein the single, maintenance injection is to be administered no sooner than 26 days after the first day of the aripiprazole treatment.

[Claim 7]

The use according to claim 3, wherein the single, maintenance injection is chosen from 160 mg and 200 mg of aripiprazole in the aripiprazole IM depot formulation when the medicament is to be administered to a patient who is a poor CYP2D6 metabolizer or has been taking concomitant CYP3A4 inhibitors or CYP2D6 inhibitors for greater than 14 days.

[Claim 8]

The use according to any one of claims 1 to 5, wherein the two, separate injections of the aripiprazole IM depot formulation are to be administered at separate gluteal injection sites of the patient.

[Claim 9]

The use according to any one of claims 1 to 5, wherein the two, separate injections of the aripiprazole IM depot formulation are to be administered at a gluteal injection site and a deltoid injection site of the patient.

[Claim 10]

The use according to any one of claims 1 to 5, wherein the two, separate injections of the aripiprazole IM depot formulation are to be administered at separate deltoid injection sites of the patient.

[Claim 11]

The use according to any one of claims1 to 10, wherein the single dose of oral aripiprazole ranges from 2 mg to 30 mg of aripiprazole.

[Claim 12]

The use according to claim 11, wherein the single dose of oral aripiprazole ranges from 10 mg to 30 mg.

[Claim 13]

The use according to claim 11, wherein the single dose of oral aripiprazole is 20 mg.

[Claim 14]

The use according to claim 11, wherein the single dose of oral aripiprazole is 10 mg.

[Claim 15]

The use according to claim 1, wherein each of the two, separate injections comprises 300 mg of aripiprazole and the single dose of oral aripiprazole is 20 mg when the medicament is to be administered to a patient who is a poor CYP2D6 metabolizer.

[Claim 16]

The use according to any one of claims 1 to 15, wherein the aripiprazole is in the form of a salt.

[Claim 17]

The use according to claim 1 or 2, wherein the medicament used in the aripiprazole treatment is to be administered to a patient with or without prior stabilization on oral aripiprazole.

[Claim 18]

The use according to claim 1 or 2, wherein the medicament used in the aripiprazole treatment is to be administered to a patient with prior stabilization on oral aripiprazole.